Fig. 1

Immune dysregulation in a founder line of CRISPR-engineered Il2ra enhancer deletion mice. a CRISPR-engineered Il2ra enhancer deletion (EDEL) founder lines that were bred for immunophenotyping. b Genomic DNA PCR to genotype the Il2ra enhancer deletion in animals from Line 2 and the immune dysregulated founder line (IDFL). c Representative CD44 surface staining on CD4+ T cells isolated from spleens of wild-type (WT) and EDEL mice from different founder lines. d Quantification of percent CD44+ cells from (c) (Lines 1 and 2: WT n = 8, EDEL n = 7; IDFL: WT n = 8, EDEL n = 7). e Representative induction of IL2RA surface expression on naive CD4+ T cells (CD4+IL2RA-CD44–) activated with anti-CD3/CD28 antibodies. f Quantification of percent IL2RA+ cells from (e) (Line 2: WT n = 4, EDEL n = 4; IDFL: WT n = 4, EDEL n = 4). g Representative IL2RA surface expression on FOXP3+CD4+T cells (Tregs) from spleen of different founders. h Quantification of normalized percent IL2RA- cells of CD4+FOXP3+ Tregs from (g) (Lines 1 and 2: WT n = 10, EDEL n = 10; IDFL: WT n = 3, EDEL n = 3). Panels (d) and (h) include data from Lines 1 and 2 animals previously published⁷. All data are presented as mean ±s.d. and are representative of at least two independent experiments. ****P ≤ 0.001 by two-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test. Raw gel image corresponding to b is shown in Supplementary Figure 7